Abciximab/Selected Platelet Inhibitors
This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.
Medical warning:
Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.
How the interaction occurs:
All of these medicines decrease your body's ability to make clots.
What might happen:
You may experience an increased chance for bleeding including bleeding from your gums, nosebleeds, unusual bruising, or dark stools.
What you should do about this interaction:
Let your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these two medicines together. They may already may be aware of this interaction and may be monitoring you for it. If your doctor prescribes these medicines together, you may need to check your bleeding times more often. Do not start, stop, or change the dosage of any medicine before checking with them first. Let your doctor know right away if you have any symptoms of bleeding.
References:
1.Aggrenox (aspirin/extended-release dipyridamole) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. September, 2012.
2.Efient (prasugrel hydrochloride) UK summary of product characteristics. Eli Lilly and Company February 25, 2009.
3.Ticlopidine hydrochloride US prescribing information. Teva Pharmaceuticals USA June, 2003.
4.ReoPro (abciximab) US prescribing information. Eli Lilly and Company November 21, 2003.
5.Kleiman NS, Graziadei N, Jordan RE, Lance ET, Fischer A, Maresh K, Edwards A, Mascelli MA. Ticlopidine enhances the platelet inhibitory capacity of abciximab in vitro. J Thromb Thrombolysis 2000 Jan;9(1):29-36.
